



MT2021-01: PTCy + Sirolimus/VIC-1911 as GVHD prophylaxis in myeloablative PBSC transplantation

Status: Recruiting

Eligibility Criteria

Conditions & Interventions

Keywords:

Clinics and Surgery Center (CSC)

More Information

Description: The primary objective of this study is to determine the optimal dose of VIC-1911 when given in combination with standard immunosuppressive therapy in adult patients undergoing myeloablative stem cell transplantation.

Contact(s): Janine Delage - jdelage@umn.edu

Principal Investigator: Punita Grover

IRB

Number: STUDY00015049

System ID: 35442

Thank you for choosing StudyFinder. Please visit http://studyfinderstaging.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.